MedPath

Combined Effect of Therapeutic Ultrasound and Trans Cutaneous Electrical Nerve Stimulation on Endometriosis

Not Applicable
Not yet recruiting
Conditions
Endometriosis
Interventions
Drug: Medical treatment
Device: Therapeutic ultrasound (US)
Device: Transcutaneous electrical nerve stimulation (TENS)
Registration Number
NCT06537765
Lead Sponsor
Cairo University
Brief Summary

This study will be conducted to investigate the combined effect of therapeutic ultrasound and transcutaneous electrical nerve stimulation (TENS) on relieving adhesions and pain related to endometriosis.

Detailed Description

Endometriosis affects 10-15% of reproductive-age women, causing pelvic pain and infertility. While laparoscopy is the primary treatment, it has risks. Medications are also used but often have side effects. Complementary therapies like acupuncture, yoga, and physical therapy modalities show promise. Therapeutic ultrasound has demonstrated effectiveness in managing chronic pain and adhesions associated with endometriosis. Transcutaneous electrical nerve stimulation (TENS) has shown positive results in pain relief and potentially improving uterine conditions for implantation. This study aims to investigate the combined effect of therapeutic ultrasound and TENS on endometriosis-related adhesion and pain, providing valuable information for physical therapists in treating this condition.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
45
Inclusion Criteria
  • Forty-five women clinically diagnosed by the gynecologist with endometriosis will be included in the study.
  • Abdominal wall endometriosis will be diagnosed via Color Doppler ultrasonography.
  • Their ages will range from 25 to 35 years old.
  • Their body mass index (BMI) will be ranged from 25 to 35 Kg/m2.
  • All patients have reported mild to moderate endometriosis symptoms such as (chronic pelvic pain (CPP), dysmenorrhea, dyspareunia, pain with bowel movements and urination and excessive bleeding) as recorded by Endometriosis Health profile questionnaire (EHP30).
  • All patients use continuous hormonal treatment for at least 3 months.
Read More
Exclusion Criteria
  • Severe endometriosis which is diagnosed by the gynecologist.
  • Pregnancy, peacemaker, epilepsy, cardiac arrhythmia, cancer, acute inflammatory pelvic disease.
  • Use of injectable hormonal therapy within the previous 6 weeks.
  • Patients with contraindication of ultrasound (Patients with reduced sensation to pain and/or heat, local malignancy, local acute infection and over areas of thrombosis or other vascular abnormalities).
  • Cognitive deficiency and difficulty to understand instructions or use the instruments.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Therapeutic ultrasound (US) GroupMedical treatmentIt will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, Therapeutic US, 3 sessions, per week for eight weeks.
Therapeutic ultrasound (US) GroupTherapeutic ultrasound (US)It will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, Therapeutic US, 3 sessions, per week for eight weeks.
Transcutaneous Electrical Nerve Stimulation (TENS) GroupMedical treatmentIt will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, TENS therapy, 3 sessions, per week for eight weeks.
Transcutaneous Electrical Nerve Stimulation (TENS) GroupTranscutaneous electrical nerve stimulation (TENS)It will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, TENS therapy, 3 sessions, per week for eight weeks.
US + TENS GroupMedical treatmentIt will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, both Therapeutic US and TENS therapy, 3 sessions, per week for eight weeks.
US + TENS GroupTherapeutic ultrasound (US)It will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, both Therapeutic US and TENS therapy, 3 sessions, per week for eight weeks.
US + TENS GroupTranscutaneous electrical nerve stimulation (TENS)It will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, both Therapeutic US and TENS therapy, 3 sessions, per week for eight weeks.
Primary Outcome Measures
NameTimeMethod
The Endometriosis Health profile (EHP30) questionnaire8 weeks

The Endometriosis Health profile (EHP30) questionnaire will be used to assess symptoms of endometriosis in all groups (A, B \& C) before and after the end of treatment program. It is self-reporting instrument that contains a core questionnaire consisting of 30 items assessing five dimensions. The five dimensions included pain, control and impotence, emotional well-being, social support, and self

-image. Each scale is converted into a score from 0 to 100, with a lower score representing a better quality of life.

The McGill pain questionnaire (MPQ)8 weeks

The pain intensity for all groups (A, B, \& C) will be assessed using the McGill Pain Questionnaire (MPQ) before and after the treatment program. The MPQ is a comprehensive tool that evaluates various dimensions of a patient's pain experience through three parts. The first part includes an anatomical drawing where the patient marks the location of their pain. The second part is a Verbal Descriptor Scale (VDS) for the patient to indicate the intensity of their current pain. The third part is an inventory of 72 descriptive adjectives to detail the pain further. The MPQ measures three key aspects: (1) the pain rating index, which assigns numerical values to each word descriptor, (2) the number of words chosen, and (3) the present pain intensity on a 1-5 scale (1 for mild, 2 for discomforting, 3 for distressing, 4 for horrible, and 5 for excruciating).

Assessment of adhesion size8 weeks

New Color Doppler Ultrasound scanner will be used in the study to assess adhesion size for all women with endometriosis in all groups (A, B, \& C) before and after the study, and this procedure will be applied by the gynecologist.

Secondary Outcome Measures
NameTimeMethod
The Health-related quality of life (HRQOL-36) questionnaire8 weeks

The Health-related quality of life (HRQOL-36) questionnaire will be used to assess health related quality of life for all women with endometriosis in all groups (A, B \& C) before and after the end of treatment program. It is a reliable and validated disease specific questionnaire with 36 questions that encompass five core scales: pain, control and powerlessness, emotional well-being, social support, and self- image. Questions are asked regarding endometriosis and are answered on a 5-points Likert scale, where 0=never, 1=rarely, 2=sometimes, 3=often, and 4=always. Raw scores for the questions within a scale are summed and transformed to a 0-100 scale, with higher scores indicating worse health-related quality of life.

© Copyright 2025. All Rights Reserved by MedPath